Aerocrine AB: Primary care trial supports FeNO-guided asthma treatment
SOLNA, Sweden — Aerocrine AB, a medical products company focused on improved management and care of patients with such inflammatory airway diseases as asthma, has announced that a new randomized clinical trial shows lower incidence of asthma exacerbations and increased asthma control with Fractional exhaled Nitric Oxide (FeNO)-guided anti-inflammatory treatment.
The study has been published on theweb site of the Journal of Allergy and Clinical Immunology: In Practice.
A total of 187 non-smoking asthma patients (ages 18 years to 64 years) with perennial allergy and on regular inhaled corticosteroid treatment were recruited at 17 primary healthcare centers in Sweden, randomly assigned to two groups and followed for one year. One group was treated with standard of care and treatment of the patients, and the other group was guided by FeNO. Aerocrine’s patented FeNO test, with the Niox Mino device was used in the study. In the standard of care group, FeNO was blinded for both patient and physician.
“FeNO-guided anti-inflammatory treatment enabled the physicians to optimize the treatment with, for example, inhaled corticosteroids, so that both over- and undertreatment can be avoided. This may be a useful tool in long-term management of patients with asthma,” stated Jörgen Syk, general practitioner at Runby primary care clinic in Stockholm, Sweden and the principal investigator in the study.
Overall, FeNO-guided management resulted in improved asthma symptom control and reduced exacerbation frequency in adults with asthma, the company stated. The FeNO-guided group reported almost 50% fewer asthma exacerbations without an increase in the used average dose of corticosteroids.
Although there was no difference in perceived quality of life, which was the primary endpoint of the study, between the groups, the FeNO-guided group reported fewer symptoms than the group following standard of care treatment.
“This is the third major, well-controlled, blinded trial to confirm that FeNO is a useful biomarker for the management of asthma by reducing exacerbations and managing the utilization of the appropriate medication at the correct time. This information further substantiates and strengthens the clinical evidence behind the American Thoracic Society guidelines. These guidelines also are endorsed by American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology,” said Scott Myers, CEO Aerocrine AB.
Teva Pharmaceuticals partners with nonprofit Volunteers in Medicine
NORTH WALES, Pa. and BURLINGTON, Vt. — Teva Pharmaceuticals USA, a subsidiary of Teva Pharmaceutical Industries, and Volunteers in Medicine, a national nonprofit organization dedicated to helping communities provide free primary healthcare clinics for families and individuals, have announced their 2014 National Partnership to make healthcare services more readily available to the uninsured.
Currently, there are 96 VIM clinics in 29 states, providing free general primary care, medications and patient education programs — as well as specialized services, such as pediatrics, dentistry, ophthalmology and counseling at some clinics – to thousands of people without access to care. This partnership will strengthen VIM’s ability to open additional clinics across the United States, increase support services to VIM clinics and promote awareness of the organization. In addition, Teva will provide monetary contributions to support the operations of VIM clinics located near a Teva business presence.
VIM supports communities by offering planning assistance at no charge to local organizing individuals or teams that have identified the need for a VIM clinic. VIM staff members guide the clinic development process, providing resources, insight and support through each phase of the clinic development process. Once open, each clinic becomes a member of the VIM Alliance, eligible to receive ongoing services from the national office.
CDC study: Severe diarrheal illness in children linked to prescribed antibiotics
NEW YORK — The majority of pediatric bacterial infections that cause severe diarrhea and are potentially life-threatening occur among children who recently took antibiotics prescribed by doctors for other conditions, according to a new study by the Centers for Disease Control and Prevention published this week in Pediatrics.
The study showed that 71% of the cases of Clostridium difficile infection identified among children ages 1 year through 17 years were community-associated — that is, not associated with an overnight stay in a healthcare facility. By contrast, two-thirds of C. difficile infections in adults are associated with hospital stays.
Among the community-associated pediatric cases whose parents were interviewed, 73% were prescribed antibiotics during the 12 weeks prior to their illness, usually in an outpatient setting, such as a doctor’s office. Most of the children who received antibiotics were being treated for ear, sinus or upper respiratory infections. Previous studies show that at least 50% of antibiotics prescribed in doctor’s offices for children are for respiratory infections, most of which do not require antibiotics.
“Improved antibiotic prescribing is critical to protect the health of our nation’s children,” stated CDC director Tom Frieden. “When antibiotics are prescribed incorrectly, our children are needlessly put at risk for health problems, including C. difficile infection and dangerous antibiotic resistant infections.”
The fiscal year 2015 President’s Budget requests funding for CDC to improve outpatient antibiotic prescribing practices and protect patients from infections, such as those caused by C. difficile. The CDC initiative aims to reduce outpatient prescribing by up to 20% and healthcare-associated C. difficile infections by 50% in five years. A 50% reduction in healthcare-associated C. difficile infections could save 20,000 lives, prevent 150,000 hospitalizations and cut more than $2 billion in healthcare costs.
C. difficile, which causes at least 250,000 infections in hospitalized patients and 14,000 deaths every year among children and adults, remains at all-time high levels. According to preliminary CDC data, an estimated 17,000 children ages 1 year through 17 years get C. difficile infections every year. The Pediatrics study found that there was no difference in the incidence of C. difficile infection among boys and girls, and that the highest numbers were seen in white children and those between the ages of 12 months and 23 months.
Taking antibiotics is the most important risk factor for developing C. difficile infections for both adults and children. When a person takes antibiotics, beneficial bacteria that protect against infection can be altered or even eliminated for several weeks to months. During this time, patients can get sick from C. difficile picked up from contaminated surfaces or spread from a healthcare provider’s hands.
Although there have been significant improvements in antibiotic prescribing for certain acute respiratory infections in children, further improvement is needed. In addition, it is critical that parents avoid asking doctors to prescribe antibiotics for their children and that doctors follow prescribing guidelines, the CDC stated.